Marine Drugs (May 2024)

Synthetic ShK-like Peptide from the Jellyfish <i>Nemopilema nomurai</i> Has Human Voltage-Gated Potassium-Channel-Blocking Activity

  • Ye-Ji Kim,
  • Yejin Jo,
  • Seung Eun Lee,
  • Jungeun Kim,
  • Jae-Pil Choi,
  • Nayoung Lee,
  • Hyokyoung Won,
  • Dong Ho Woo,
  • Seungshic Yum

DOI
https://doi.org/10.3390/md22050217
Journal volume & issue
Vol. 22, no. 5
p. 217

Abstract

Read online

We identified a new human voltage-gated potassium channel blocker, NnK-1, in the jellyfish Nemopilema nomurai based on its genomic information. The gene sequence encoding NnK-1 contains 5408 base pairs, with five introns and six exons. The coding sequence of the NnK-1 precursor is 894 nucleotides long and encodes 297 amino acids containing five presumptive ShK-like peptides. An electrophysiological assay demonstrated that the fifth peptide, NnK-1, which was chemically synthesized, is an effective blocker of hKv1.3, hKv1.4, and hKv1.5. Multiple-sequence alignment with cnidarian Shk-like peptides, which have Kv1.3-blocking activity, revealed that three residues (3Asp, 25Lys, and 34Thr) of NnK-1, together with six cysteine residues, were conserved. Therefore, we hypothesized that these three residues are crucial for the binding of the toxin to voltage-gated potassium channels. This notion was confirmed by an electrophysiological assay with a synthetic peptide (NnK-1 mu) where these three peptides were substituted with 3Glu, 25Arg, and 34Met. In conclusion, we successfully identified and characterized a new voltage-gated potassium channel blocker in jellyfish that interacts with three different voltage-gated potassium channels. A peptide that interacts with multiple voltage-gated potassium channels has many therapeutic applications in various physiological and pathophysiological contexts.

Keywords